---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-302356"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:00:10.691090+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio raises ~$100M via equity and debt; affiliate converts $56.6M note into equity

## Summary
- Registered direct offering: 9,090,909 shares + warrants at $5.50 per unit, gross $50M.
- New $50M promissory note from Nant Capital (affiliated with Dr. Soon-Shiong) at Term SOFR + 8%, due Dec 2023.
- NantWorks converts ~$56.6M existing principal and accrued interest into common at $5.67/share.
- Pro forma cash and securities ~$160M after net proceeds of ~$96.4M from equity and debt.
- If fully exercised, warrants could yield up to $60M additional gross proceeds over two years.

## SEC filing metadata
- accession: 0001193125-22-302356
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-302356
- JSON: https://secwatch.observer/filing/0001193125-22-302356.json
- Plain text: https://secwatch.observer/filing/0001193125-22-302356.txt

## Key facts
- Debt Financings
  ImmunityBio, Inc. incurred loan of $50.0 million with Nant Capital, LLC at Term SOFR plus 8.0% per annum maturing December 31, 2023.
  - Instrument: loan
  - Principal: $50.0 million
  - Counterparty: Nant Capital, LLC
  - Rate: Term SOFR plus 8.0% per annum
  - Maturity: December 31, 2023
  - Event: incurrence
  source text: On December 12, 2022, the Company executed a $50.0 million promissory note with Nant Capital, LLC
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm
- Material Agreements
  ImmunityBio, Inc. entered into the “SPA” with an institutional investor valued at $50.0 million (effective 2022-12-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Value: $50.0 million
  - Effective: 2022-12-12
  source text: On December 12, 2022, ImmunityBio, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with an institutional investor (the “Investor”) for the purchase and sale in a registered direct offering of 9,090,909 shares of the Company’s common stock and warrants to purchase an additional 9,090,909 shares at an exercise price of $6.60 per share for a purchase price of $5.50 per share and accompanying warrant, generating gross proceeds from the offering of approximately $50.0 million before deducting placement agent fees and other estimated offering expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm
- Material Agreements
  ImmunityBio, Inc. entered into $50.0 million promissory note with Nant Capital, LLC valued at $50.0 million (effective 2022-12-12).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Nant Capital, LLC
  - Value: $50.0 million
  - Effective: 2022-12-12
  source text: On December 12, 2022, the Company executed a $50.0 million promissory note with Nant Capital, LLC (“Nant Capital”), an entity affiliated with Dr. Patrick Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm
- Material Agreements
  ImmunityBio, Inc. entered into the “PAA” with Piper Sandler & Co. valued at cash fee equal to 6.0% of the gross proceeds (effective 2022-12-12).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Piper Sandler & Co.
  - Value: cash fee equal to 6.0% of the gross proceeds
  - Effective: 2022-12-12
  source text: On December 12, 2022, the Company also entered into a placement agency agreement (the “PAA”) with Piper Sandler & Co. (the “Placement Agent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.